Caldera Therapeutics Overview
- Year Founded
-
2025
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
PIPE
- (In Progress)
- Latest Deal Amount
-
$278M
- Investors
-
7
Caldera Therapeutics General Information
Description
Caldera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of the investigational bispecific antibody CLD-423 for the treatment of inflammatory bowel disease (IBD) and other immune-mediated diseases. CLD-423 is designed to simultaneously inhibit two clinically validated inflammatory pathways, Tumor Necrosis Factor (TNF)-like ligand 1A (TL1A) and interleukin (IL)-23p19.
Contact Information
Website
www.calderatx.comCorporate Office
- 300 Technology Square
- 8th Floor
- Cambridge, MA 02139
- United States
Corporate Office
- 300 Technology Square
- 8th Floor
- Cambridge, MA 02139
- United States
Caldera Therapeutics Timeline
Caldera Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. PIPE | 29-Jul-2026 | $278M | In Progress | Clinical Trials - Phase 1 | ||
| 3. Reverse Merger | 29-Jul-2026 | Announced | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A1) | 08-Jan-2026 | $37.5M | $112M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC (Series A) | 01-Apr-2025 | $75M | $75M | Completed | Pre-Clinical Trials |
Caldera Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Caldera Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Caldera Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Caldera Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Janus Henderson Investors | Asset Manager | Minority | ||
| LifeSci Venture Partners | Corporate Venture Capital | Minority | ||
| Omega Funds | Venture Capital | Minority | ||
| Wellington Management | Asset Manager | Minority | ||
| Atlas Venture | Venture Capital | Minority |
Caldera Therapeutics Acquisitions (1)
Caldera Therapeutics’s most recent deal was a Merger/Acquisition with Synlogic. The deal was made on 29-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Synlogic | 29-Jul-2026 | Merger/Acquisition | Drug Discovery |
Caldera Therapeutics FAQs
-
When was Caldera Therapeutics founded?
Caldera Therapeutics was founded in 2025.
-
Where is Caldera Therapeutics headquartered?
Caldera Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Caldera Therapeutics?
Caldera Therapeutics has 10 total employees.
-
What industry is Caldera Therapeutics in?
Caldera Therapeutics’s primary industry is Drug Discovery.
-
Is Caldera Therapeutics a private or public company?
Caldera Therapeutics is a Private company.
-
What is Caldera Therapeutics’s current revenue?
The current revenue for Caldera Therapeutics is .
-
How much funding has Caldera Therapeutics raised over time?
Caldera Therapeutics has raised $112M.
-
Who are Caldera Therapeutics’s investors?
Janus Henderson Investors, LifeSci Venture Partners, Omega Funds, Wellington Management, and Atlas Venture are 5 of 7 investors who have invested in Caldera Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
